Sionna Therapeutics halts cystic fibrosis drug development after trial failure

On August 10, 2026, Sionna Therapeutics announced it will halt development of its experimental cystic fibrosis drug, SION-719, after it failed to show benefit as an add-on to Vertex's Trikafta in a Phase 2 trial. The drug failed to significantly lower sweat chloride levels in 15 adult patients. Following the news, Sionna's stock plummeted up to 92% in pre-market trading, prompting the company to plan capital preservation measures, including potential layoffs, while reviewing its pipeline.

SION-719 trial failure

• ▪The Phase 2 clinical trial of SION-719 tested the drug as an add-on to Vertex Pharmaceuticals' Trikafta in 15 adults with cystic fibrosis
• ▪Sionna Therapeutics announced on August 10, 2026, that it will stop developing its experimental drug SION-719 as an add-on therapy for cystic fibrosis
• ▪SION-719 was generally well tolerated during a 14-day Phase 2 study, with mostly mild to moderate side effects and no serious side effects reported

Sweat chloride outcome measure

• ▪Sionna Therapeutics stated that variations in patient test results and differences in Trikafta levels may have influenced the SION-719 trial outcome
• ▪Sionna Therapeutics' stock fell between 90% and 92% in pre-market trading on August 10, 2026, following the SION-719 trial failure announcement

Capital preservation strategy

• ▪Sionna Therapeutics is separately developing a two-drug cystic fibrosis treatment combining the experimental compounds SION-451 and SION-2222
• ▪Sionna Therapeutics CEO Mike Cloonan expressed disappointment in the unexpected SION-719 trial results and stated the company is reviewing the data before deciding its next steps
• ▪Sionna Therapeutics announced on August 10, 2026, that it will take actions to preserve capital, hinting at potential layoffs, while evaluating its next steps